Eli Lilly Comprehensive Income 2010-2024 | LLY

Eli Lilly comprehensive income for the quarter ending September 30, 2024 was $-4.275B, a 12.94% increase year-over-year.

  • Eli Lilly comprehensive income for 2023 was $-4.327B, a 12.55% increase from 2022.
  • Eli Lilly comprehensive income for 2022 was $-3.845B, a 11.48% decline from 2021.
  • Eli Lilly comprehensive income for 2021 was $-4.343B, a 33.15% decline from 2020.

Eli Lilly Comprehensive Income 2010-2024 | LLY

  • Eli Lilly comprehensive income for 2023 was $-4.327B, a 12.55% increase from 2022.
  • Eli Lilly comprehensive income for 2022 was $-3.845B, a 11.48% decline from 2021.
  • Eli Lilly comprehensive income for 2021 was $-4.343B, a 33.15% decline from 2020.
Related Stocks
Company NameMarket
Cap
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B